# HBEGF

## Overview
Heparin-binding EGF-like growth factor (HBEGF) is a gene that encodes a member of the epidermal growth factor (EGF) family, known for its role in cellular growth, proliferation, and differentiation. The protein product, also referred to as HB-EGF, is a growth factor that can exist in both a transmembrane and a soluble form, each playing distinct roles in cellular signaling. As a ligand for the EGF receptor (EGFR) and ErbB4, HB-EGF is involved in activating signaling pathways that are crucial for various physiological processes, including wound healing, tissue repair, and cardiac development (Iwamoto2006ErbB; Nishi2004Heparinbinding). The protein is characterized by its heparin-binding domain, which facilitates interactions with cell surface heparan sulfate proteoglycans, enhancing its bioactivity and receptor binding (Freeman1997Heparinbinding). Dysregulation of HBEGF expression is associated with several pathological conditions, including cancer and cardiac dysfunction, highlighting its significance in both health and disease (Shin2017HBEGF; Jackson2003Defective).

## Structure
Heparin-binding EGF-like growth factor (HBEGF) is a member of the epidermal growth factor (EGF) family, characterized by a conserved EGF domain. This domain includes six cysteine residues that form three disulfide bonds, creating loops A, B, and C, which are crucial for maintaining the protein's functional conformation and enabling receptor interaction (Ferreira2022A). The primary structure of HBEGF includes a signal peptide and an EGF-like domain. The secondary structure typically involves alpha-helices and beta-sheets, while the tertiary structure is compact and globular, stabilized by disulfide bonds (Ferreira2022A).

HBEGF is initially synthesized as a transmembrane precursor, which can be cleaved to release a soluble form. This cleavage is essential for its biological activity, as both the membrane-bound and soluble forms can interact with epidermal growth factor receptors (EGFR), leading to receptor dimerization and activation of signaling pathways (Krynina2019Role). HBEGF can undergo post-translational modifications such as glycosylation and phosphorylation, and it may exist in different isoforms due to alternative splicing (Cramer2019Soluble). The heparin-binding domain plays a significant role in intracellular trafficking and receptor interaction (Krynina2019Role).

## Function
HBEGF (heparin-binding EGF-like growth factor) is a member of the EGF family that plays a significant role in various physiological processes. It functions as a ligand for the EGF receptor (EGFR) and ErbB4, activating these receptors to initiate signaling pathways crucial for cell proliferation, differentiation, and survival (Iwamoto2006ErbB). HBEGF is synthesized as a transmembrane protein, proHB-EGF, which can be cleaved to release a soluble form that acts in a juxtacrine manner to signal neighboring cells (Nishi2004Heparinbinding).

In healthy human cells, HBEGF is involved in wound healing, tissue repair, and development. It promotes angiogenesis by inducing migration and tube formation in endothelial cells through the activation of EGFR, PI3K, and ERK1/2 pathways, independent of VEGF (Mehta2007HBEGF). HBEGF also plays a role in cardiac development and function, as demonstrated by its involvement in heart valve formation and homeostasis (Iwamoto2006ErbB).

HBEGF is active in various cellular locations, including the cell membrane and extracellular space, where it interacts with cell surface heparan sulfate proteoglycans (HSPGs) to mediate cellular responses (Freeman1997Heparinbinding). Its expression is regulated by inflammatory cytokines, growth factors, and physical stress, highlighting its role in immediate early gene responses (Nishi2004Heparinbinding).

## Clinical Significance
Mutations and alterations in the expression of the HBEGF gene are associated with several diseases and conditions. In cardiac development, the absence or disruption of HBEGF leads to defective cardiac valvulogenesis, characterized by enlarged and stenotic heart valves. This is due to its role as a ligand for the epidermal growth factor receptor (EGFR), which is crucial for normal heart valve development (Jackson2003Defective). HB-EGF-null mice exhibit severe cardiac dysfunction, including ventricular dilation and cardiomyocyte hypertrophy, indicating its essential role in maintaining cardiac function (Iwamoto2003Heparinbinding).

In cancer, HBEGF is implicated in the progression of various malignancies, including glioblastoma, where it promotes tumor growth and is associated with a worse prognosis. Its overexpression is linked to reduced survival in patients with glioblastoma (Shin2017HBEGF). HBEGF is also overexpressed in ovarian, gastric, and breast cancers, and targeting it with small interference RNA has shown potential in increasing apoptosis and reducing cancer cell proliferation (Yotsumoto2008Validation).

Alterations in HBEGF expression are also linked to dilated cardiomyopathy, where its deficiency leads to impaired cardiac function due to disrupted signaling through ERBB2/B4 receptors (Friedrichs2008HBEGF).

## Interactions
Heparin-binding EGF-like growth factor (HB-EGF) is involved in various protein interactions that influence its biological functions. The transmembrane form, proHB-EGF, forms complexes with several membrane proteins, including CD9/DRAP27, which enhances sensitivity to diphtheria toxin by increasing the number of functional toxin receptors (Nishi2004Heparinbinding). ProHB-EGF also interacts with integrin α3β1 at cell-cell contact sites in epithelial cells, facilitating cell adhesion and signaling (Izumi1998A; Nishi2004Heparinbinding).

HB-EGF interacts with the cochaperone BAG-1 through its cytoplasmic domain, which may contribute to its cytoprotective effects (Harris2003EGF). It also forms a complex with CD44HSPG and MMP-7, which processes proHB-EGF to its mature form, allowing it to engage and activate ErbB4, leading to cell survival and tissue remodeling (Yu2002CD44).

Mature HB-EGF binds to several receptors, including EGFR (HER1), HER4, and NRDc, a non-tyrosine kinase receptor, leading to enhanced cell migration and proliferation (Nishi2004Heparinbinding). It also interacts with heparan sulfate proteoglycans (HSPGs), which enhance its binding to EGFR and its bioactivity (Harris2003EGF). These interactions are crucial for HB-EGF's role in cellular processes such as proliferation, differentiation, and survival.


## References


[1. (Harris2003EGF) R Harris. Egf receptor ligands. Experimental Cell Research, 284(1):2–13, March 2003. URL: http://dx.doi.org/10.1016/s0014-4827(02)00105-2, doi:10.1016/s0014-4827(02)00105-2. This article has 598 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0014-4827(02)00105-2)

[2. (Mehta2007HBEGF) Veela B. Mehta, Gail E. Besner, Veela B. Mehta, and Gail E. Besner. Hb-egf promotes angiogenesis in endothelial cells via pi3-kinase and mapk signaling pathways. Growth Factors, 25(4):253–263, January 2007. URL: http://dx.doi.org/10.1080/08977190701773070, doi:10.1080/08977190701773070. This article has 113 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/08977190701773070)

[3. (Ferreira2022A) Arthur Schveitzer Ferreira, Amanda Lopacinski, Michel Batista, Priscila Mazzocchi Hiraiwa, Beatriz Gomes Guimarães, and Nilson Ivo Tonin Zanchin. A toolkit for recombinant production of seven human egf family growth factors in active conformation. Scientific Reports, March 2022. URL: http://dx.doi.org/10.1038/s41598-022-09060-9, doi:10.1038/s41598-022-09060-9. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-022-09060-9)

[4. (Iwamoto2006ErbB) Ryo Iwamoto and Eisuke Mekada. Erbb and hb-egf signaling in heart development and function. Cell Structure and Function, 31(1):1–14, 2006. URL: http://dx.doi.org/10.1247/CSF.31.1, doi:10.1247/csf.31.1. This article has 164 citations and is from a peer-reviewed journal.](https://doi.org/10.1247/CSF.31.1)

[5. (Nishi2004Heparinbinding) Eiichiro Nishi and Michael Klagsbrun. Heparin-binding epidermal growth factor-like growth factor (hb-egf) is a mediator of multiple physiological and pathological pathways. Growth Factors, 22(4):253–260, December 2004. URL: http://dx.doi.org/10.1080/08977190400008448, doi:10.1080/08977190400008448. This article has 61 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/08977190400008448)

[6. (Izumi1998A) Y. Izumi. A metalloprotease-disintegrin, mdc9/meltrin-gamma /adam9 and pkcdelta are involved in tpa-induced ectodomain shedding of membrane-anchored heparin-binding egf-like growth factor. The EMBO Journal, 17(24):7260–7272, December 1998. URL: http://dx.doi.org/10.1093/emboj/17.24.7260, doi:10.1093/emboj/17.24.7260. This article has 411 citations.](https://doi.org/10.1093/emboj/17.24.7260)

[7. (Yu2002CD44) Wei-Hsuan Yu, J. Frederick Woessner, John D. McNeish, and Ivan Stamenkovic. Cd44 anchors the assembly of matrilysin/mmp-7 with heparin-binding epidermal growth factor precursor and erbb4 and regulates female reproductive organ remodeling. Genes &amp; Development, 16(3):307–323, February 2002. URL: http://dx.doi.org/10.1101/gad.925702, doi:10.1101/gad.925702. This article has 351 citations.](https://doi.org/10.1101/gad.925702)

[8. (Cramer2019Soluble) Megan L. Cramer, Rui Xu, and Paul T. Martin. Soluble heparin binding epidermal growth factor-like growth factor is a regulator of galgt2 expression and galgt2-dependent muscle and neuromuscular phenotypes. Molecular and Cellular Biology, July 2019. URL: http://dx.doi.org/10.1128/mcb.00140-19, doi:10.1128/mcb.00140-19. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.00140-19)

[9. (Yotsumoto2008Validation) Fusanori Yotsumoto, Hiroshi Yagi, Satoshi O. Suzuki, Eiji Oki, Hiroshi Tsujioka, Touru Hachisuga, Kenzo Sonoda, Tatsuhiko Kawarabayashi, Eisuke Mekada, and Shingo Miyamoto. Validation of hb-egf and amphiregulin as targets for human cancer therapy. Biochemical and Biophysical Research Communications, 365(3):555–561, January 2008. URL: http://dx.doi.org/10.1016/j.bbrc.2007.11.015, doi:10.1016/j.bbrc.2007.11.015. This article has 100 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2007.11.015)

[10. (Friedrichs2008HBEGF) Frauke Friedrichs, Christian Zugck, Gerd-Jörg Rauch, Boris Ivandic, Dieter Weichenhan, Margit Müller-Bardorff, Benjamin Meder, Nour Eddine El Mokhtari, Vera Regitz-Zagrosek, Roland Hetzer, Arne Schäfer, Stefan Schreiber, Jian Chen, Isaac Neuhaus, Ruiru Ji, Nathan O. Siemers, Norbert Frey, Wolfgang Rottbauer, Hugo A. Katus, and Monika Stoll. Hbegf, sra1, and ik: three cosegregating genes as determinants of cardiomyopathy. Genome Research, 19(3):395–403, December 2008. URL: http://dx.doi.org/10.1101/gr.076653.108, doi:10.1101/gr.076653.108. This article has 79 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1101/gr.076653.108)

[11. (Jackson2003Defective) L. F. Jackson. Defective valvulogenesis in hb-egf and tace-null mice is associated with aberrant bmp signaling. The EMBO Journal, 22(11):2704–2716, June 2003. URL: http://dx.doi.org/10.1093/emboj/cdg264, doi:10.1093/emboj/cdg264. This article has 337 citations.](https://doi.org/10.1093/emboj/cdg264)

[12. (Freeman1997Heparinbinding) M R Freeman, J J Yoo, G Raab, S Soker, R M Adam, F X Schneck, A A Renshaw, M Klagsbrun, and A Atala. Heparin-binding egf-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder. Journal of Clinical Investigation, 99(5):1028–1036, March 1997. URL: http://dx.doi.org/10.1172/JCI119230, doi:10.1172/jci119230. This article has 190 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/JCI119230)

[13. (Krynina2019Role) O. I. Krynina, K. Yu. Manoilov, D. V. Kolybo, and S. V. Komisarenko. Role of the heparin-binding domain in intracellular trafficking of shb-egf. The Ukrainian Biochemical Journal, 91(4):26–32, June 2019. URL: http://dx.doi.org/10.15407/ubj91.04.026, doi:10.15407/ubj91.04.026. This article has 0 citations.](https://doi.org/10.15407/ubj91.04.026)

[14. (Iwamoto2003Heparinbinding) Ryo Iwamoto, Satoru Yamazaki, Masanori Asakura, Seiji Takashima, Hidetoshi Hasuwa, Kenji Miyado, Satoshi Adachi, Masafumi Kitakaze, Koji Hashimoto, Gerhard Raab, Daisuke Nanba, Shigeki Higashiyama, Masatsugu Hori, Michael Klagsbrun, and Eisuke Mekada. Heparin-binding egf-like growth factor and erbb signaling is essential for heart function. Proceedings of the National Academy of Sciences, 100(6):3221–3226, March 2003. URL: http://dx.doi.org/10.1073/pnas.0537588100, doi:10.1073/pnas.0537588100. This article has 284 citations.](https://doi.org/10.1073/pnas.0537588100)

[15. (Shin2017HBEGF) C H Shin, J P Robinson, J A Sonnen, A E Welker, D X Yu, M W VanBrocklin, and S L Holmen. Hbegf promotes gliomagenesis in the context of ink4a/arf and pten loss. Oncogene, 36(32):4610–4618, April 2017. URL: http://dx.doi.org/10.1038/onc.2017.83, doi:10.1038/onc.2017.83. This article has 15 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2017.83)